Analyst Research

Report Title Price
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc receives Orphan Drug designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease


Monday, 21 Apr 2014 07:00am EDT 

Emergent BioSolutions Inc:U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis.Orphan status is given to drugs and biologics that are being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in U.S.This designation provides incentives to BioThrax PEP Program, including waiver of Biologics License Application (BLA) supplemental regulatory filing fee and marketing exclusivity of up to seven years. 

Company Quote

35.88
0.68 +1.93%
12 Feb 2016